Cumberland Pharmaceuticals (CPIX) News
NASDAQ: CPIXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CPIX news summary
We found 11 recent headlines mentioning Cumberland Pharmaceuticals (CPIX): 2 in the past week and 8 in the past 30 days, most often from PR Newswire, Nasdaq. CPIX is making an outsized move today, down 7.30% at $5.84, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Cumberland Pharmaceuticals Inc. Announces Phase 2a ASSIST-SSc Trial Top-Line Results", was published by Nasdaq on Nov 17, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Cumberland Pharmaceuticals headlines
- Cumberland Pharmaceuticals Inc. Announces Phase 2a ASSIST-SSc Trial Top-Line ResultsCumberland Pharmaceuticals Inc. announced top-line results from its Phase 2a ASSIST-SSc trial evaluating oral ifetroban for patients with systemic sclerosis. The 12-month pilot trial evaluated the…Nasdaq
- Cumberland Pharmaceuticals Inc. Announces Plans to File New Drug Application for Ifetroban DMD ProgramCumberland Pharmaceuticals Inc. announced plans to submit a New Drug Application to the U.S. Food and Drug Administration for its ifetroban product candidate as a potential treatment for the…NasdaqCPIX, HEI.A
- CUMBERLAND PHARMACEUTICALS REPORTS Q3 2026 FINANCIAL RESULTS & COMPANY UPDATE$100 million Strategic Transaction Closed Plans to Submit New Drug Application for Ifetroban in DMD Top-Line Results Announced for Systemic Sclerosis Trial NASHVILLE, Tenn., Nov. 10, 2026…PR Newswire
- CUMBERLAND PHARMACEUTICALS TO ANNOUNCE COMPANY UPDATE & Q3 2026 FINANCIAL RESULTSNASHVILLE, Tenn., Nov. 3, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-focused biopharmaceutical company committed to developing new products for rare diseases,…PR Newswire
- CUMBERLAND PHARMACEUTICALS ANNOUNCES PLANS TO FILE NEW DRUG APPLICATION FOR IFETROBAN DMD PROGRAMNASHVILLE, Tenn., Oct. 26, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), ("Cumberland" or the "Company") an innovation-focused biopharmaceutical company developing new products…PR Newswire
- Cumberland Pharma Reports Phase 2a Safety Data For Ifetroban In Systemic Sclerosis; Shares Slide(RTTNews) - Cumberland Pharmaceuticals Inc. (CPIX) reported results from its Phase 2a ASSIST-SSc trial evaluating oral ifetroban in patients with systemic sclerosis (SSc), with the study supporting…NasdaqCPIX, HEI.A
- Cumberland Pharmaceuticals Inc. Announces Top-Line Results from Phase 2a ASSIST-SSc TrialOn October 23, 2026, Cumberland Pharmaceuticals Inc. announced top-line results from its Phase 2a ASSIST-SSc trial evaluating oral ifetroban for patients with systemic sclerosis. These results…Nasdaq
- Cumberland Pharmaceuticals Announces ASSIST-SSc Trial Top-Line ResultsIfetroban was well tolerated in patients with systemic sclerosis NASHVILLE, Tenn., Oct. 23, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), an innovation-driven biopharmaceutical…PR Newswire
- CUMBERLAND PHARMACEUTICALS PROVIDES UPDATED WEBCAST REGISTRATION LINK FOR IFETROBAN DMD PROGRAM CALLNASHVILLE, Tenn., Oct. 23, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-driven biopharmaceutical company advancing new therapies that address significant unmet…PR Newswire
- Tuesday Sector Leaders: Biotechnology, DrugsIn trading on Tuesday, biotechnology shares were relative leaders, up on the day by about 4.2%. Leading the group were shares of Myriad Genetics, up about 37.5% and shares of Larimar Therapeutics up…NasdaqMYGN, LRMR, ABOS, CPIX
- CUMBERLAND PHARMACEUTICALS ANNOUNCES NATIONAL CALL TO PRESENT AN UPDATE ON ITS IFETROBAN DMD PROGRAMNASHVILLE, Tenn., Oct. 19, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-driven biopharmaceutical company advancing new therapies that address significant unmet…PR Newswire